Alcobra Pharma (ADHD) reports that the Phase 3 clinical trial of MDX in adults with ADHD missed the primary endpoint

Alcobra Pharma reports that the Phase 3 clinical trial of MDX in adults with ADHD missed the primary endpoint :

In this trial, MDX did not meet the primary endpoint of demonstrating a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners' Adult ADHD Rating Scales (:CAARS). As previously communicated, the top-line data analysis was conducted on the Full Analysis Set (n=283), which includes all randomized subjects with at least one post-baseline efficacy assessment. Consistent with previously conducted studies, MDX was generally well tolerated.

• "We are exceedingly disappointed with these top-line results. In the coming weeks, the Company intends to review the full data set from MEASURE. Consequently, we will evaluate our options and communicate our strategic plan to investors"